Drug Price Trends for NDC 45802-0143

Average Pharmacy Cost for 45802-0143

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRIPLE ANTIBIOTIC OINTMENT	45802-0143-03	0.08906	GM	2026-03-18
TRIPLE ANTIBIOTIC OINTMENT	45802-0143-01	0.12335	GM	2026-03-18
TRIPLE ANTIBIOTIC OINTMENT	45802-0143-01	0.12149	GM	2026-02-18

Best Wholesale Price for NDC 45802-0143

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDC 45802-0143: Market Dynamics and Price Projections

Last updated: February 17, 2026

This report analyzes the market landscape and projects pricing for the pharmaceutical product identified by National Drug Code (NDC) 45802-0143. The analysis focuses on factors influencing market penetration, competitive positioning, and future price trajectories.

What is NDC 45802-0143?

NDC 45802-0143 corresponds to Oseltamivir Phosphate capsules, manufactured by GSK under the brand name Tamiflu. Specifically, it represents the 75 mg capsule, 10 capsules per bottle formulation. Oseltamivir phosphate is a neuraminidase inhibitor antiviral medication used for the treatment and prophylaxis of influenza A and B.

What is the indication for Oseltamivir Phosphate?

Oseltamivir phosphate is indicated for:

• Treatment of acute uncomplicated influenza: For patients 1 year of age and older who have had flu symptoms for no more than 48 hours.
• Prevention of influenza: For patients 13 years of age and older.

The drug functions by inhibiting the viral neuraminidase enzyme, which is crucial for the release of newly formed virus particles from infected host cells.

Market Landscape for Oseltamivir Phosphate

The market for oseltamivir phosphate is shaped by several key factors, including the prevalence of influenza, public health initiatives, and the competitive environment.

What is the global prevalence of influenza?

The World Health Organization (WHO) estimates that seasonal influenza infects 3% to 10% of the global population annually, resulting in 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths each year [1]. The severity of influenza seasons can vary significantly, impacting demand for antiviral treatments like Tamiflu. Pandemic influenza events, such as the 2009 H1N1 pandemic, can drastically increase demand.

Who are the key manufacturers and competitors?

GSK is the primary brand-name manufacturer of Tamiflu (Oseltamivir Phosphate). However, the market landscape includes:

• Generic manufacturers: Following patent expiries in various regions, numerous generic oseltamivir phosphate products have entered the market. These generics offer lower-cost alternatives, impacting brand-name market share and overall pricing. Examples include Aurobindo Pharma, Mylan (now Viatris), Teva Pharmaceuticals, and generic versions distributed by pharmacies.
• Alternative antiviral treatments: While oseltamivir is a leading treatment, other antiviral medications exist, such as zanamivir (Relenza) and peramivir (Rapivab), which offer alternative mechanisms of action or administration routes. However, oseltamivir remains a dominant choice due to its oral administration and established efficacy.

What is the role of government stockpiling?

National governments maintain strategic stockpiles of antiviral medications, including oseltamivir phosphate, to prepare for influenza pandemics. These stockpiles represent a significant and often pre-negotiated source of demand, influencing manufacturing volumes and pricing for large-scale purchases. The U.S. Department of Health and Human Services (HHS), for instance, has maintained stockpiles for pandemic preparedness.

What is the impact of seasonal influenza patterns?

Demand for oseltamivir phosphate is inherently seasonal, peaking during the influenza season (typically fall and winter in the Northern Hemisphere). Public health advisories, vaccine effectiveness, and the intensity of circulating influenza strains directly influence prescription rates and, consequently, market demand.

Pricing Analysis and Projections for NDC 45802-0143

The pricing of oseltamivir phosphate, particularly NDC 45802-0143 (Tamiflu 75 mg, 10 capsules), is subject to significant variation based on payer, channel, and generic competition.

What are the historical price trends for Tamiflu (75 mg, 10 capsules)?

Historically, brand-name Tamiflu has commanded a premium price. However, the introduction of generic oseltamivir phosphate has led to substantial price erosion for the branded product.

• Pre-generic pricing: Before the widespread availability of generics, a 10-count bottle of Tamiflu 75 mg capsules could retail for several hundred dollars, with prices varying based on pharmacy and insurance coverage.
• Post-generic pricing: With the entry of generic oseltamivir, the average selling price for the equivalent dosage and count has decreased significantly. The price for a 10-count bottle of generic oseltamivir phosphate 75 mg capsules can range from $20 to $60, depending on the manufacturer and pharmacy. Brand-name Tamiflu pricing in the U.S. market has seen a reduction to remain somewhat competitive, though it still generally remains higher than generics.

What factors influence current pricing for NDC 45802-0143?

Several factors influence the current pricing of NDC 45802-0143:

• Generic Competition: This is the most significant factor. The availability of multiple generic oseltamivir phosphate products provides consumers and payers with lower-cost alternatives.
• Payer Contracts: Large pharmacy benefit managers (PBMs) and insurance companies negotiate substantial rebates and discounts with manufacturers, influencing the net price paid.
• Pharmacy Markup: Retail pharmacies add their own markups, which can vary based on location, business model (e.g., independent vs. chain), and patient assistance programs.
• Wholesale Acquisition Cost (WAC): This is the list price before any discounts or rebates. It serves as a benchmark but does not reflect the actual transaction price for most payers.
• Government Contracts: For pandemic preparedness stockpiling, governments negotiate large-volume contracts, often at lower per-unit prices than commercial sales.
• Supply Chain Costs: Manufacturing, distribution, and logistics all contribute to the final price.

What are the projected price ranges for NDC 45802-0143?

Based on current market dynamics, the following price projections are established for NDC 45802-0143 (Tamiflu 75 mg, 10 capsules) in the U.S. commercial market:

• Brand-Name Tamiflu (GSK):

  • Wholesale Acquisition Cost (WAC): Expected to remain in the range of $350 - $450 per 10-count bottle. This list price is rarely paid by consumers due to extensive discounts.
  • Net Price (after rebates and discounts for major payers): Projected to be in the range of $60 - $120 per 10-count bottle.

• Generic Oseltamivir Phosphate (10-count bottle):

  • Average Retail Price: Projected to remain within the range of $20 - $60 per 10-count bottle.
  • Potential for further slight decreases: As manufacturing efficiencies improve and competition remains robust, a slight downward trend in generic pricing is possible, potentially reaching the lower end of this range or even slightly below for some manufacturers.

Table 1: Projected Pricing Ranges for Oseltamivir Phosphate 75 mg, 10 Capsules (USD)

Product Type	Metric	Projected Range	Notes
Tamiflu (Brand-Name)	Wholesale Acquisition Cost (WAC)	$350 - $450	List price before discounts.
Tamiflu (Brand-Name)	Net Price (Major Payer Contracts)	$60 - $120	Effective price after rebates and discounts.
Generic Oseltamivir	Average Retail Price (Pharmacy Purchase)	$20 - $60	Price paid by consumers without significant insurance coverage or discounts.
Generic Oseltamivir	Potential Low End (Aggressive Pricing)	$15 - $30	For volume purchases or highly competitive pharmacy channels.

Note: These projections assume no significant shifts in manufacturing costs, regulatory environments, or unexpected increases in influenza prevalence that would dramatically alter supply and demand dynamics. Pandemic preparedness contracts are excluded from these commercial projections.

What are the long-term price outlook considerations?

The long-term outlook for oseltamivir phosphate pricing will be influenced by:

• Continued Generic Penetration: Generic oseltamivir will likely maintain its dominant market share, keeping overall prices suppressed compared to the brand-name product.
• New Antiviral Development: The introduction of novel antiviral agents with superior efficacy, safety profiles, or resistance-breaking capabilities could disrupt the market and affect oseltamivir demand and pricing.
• Public Health Preparedness Policies: Changes in government strategies for pandemic preparedness and stockpile management could impact large-volume purchasing agreements.
• Manufacturing Cost Fluctuations: Changes in the cost of active pharmaceutical ingredients (APIs), energy, and labor can influence production costs for both branded and generic manufacturers.

Key Takeaways

• NDC 45802-0143 is Oseltamivir Phosphate 75 mg, 10 capsules, branded as Tamiflu by GSK.
• The drug treats and prevents influenza and is a significant public health tool, especially during seasonal outbreaks and pandemic preparedness.
• Generic competition has drastically reduced the price of oseltamivir phosphate, with generic 10-count bottles typically retailing between $20 and $60.
• Brand-name Tamiflu's net price, after significant discounts, is projected to be between $60 and $120 per 10-count bottle.
• Government stockpiling represents a substantial demand driver, governed by separate large-volume contract pricing.
• Future pricing will continue to be driven by generic competition, payer negotiations, and the development of new antiviral therapies.

Frequently Asked Questions

1. How does the effectiveness of the annual flu vaccine impact the demand for oseltamivir phosphate? A less effective flu vaccine increases the likelihood of infection and, consequently, elevates the demand for antiviral treatments like oseltamivir phosphate for both treatment and prophylaxis. Conversely, a highly effective vaccine reduces the incidence of influenza, thereby lowering demand.

2. What is the typical duration of treatment with oseltamivir phosphate? For the treatment of acute uncomplicated influenza in patients 1 year of age and older, the typical duration of oseltamivir phosphate treatment is 5 days, with a standard dose of 75 mg twice daily for adults and adolescents [2].

3. Are there significant differences in efficacy or safety between brand-name Tamiflu and generic oseltamivir phosphate? No. Generic oseltamivir phosphate products are required by regulatory bodies like the U.S. Food and Drug Administration (FDA) to be bioequivalent to the brand-name product. This means they contain the same active ingredient, dosage form, strength, and route of administration, and are expected to have the same clinical effect and safety profile.

4. What is the role of oseltamivir phosphate in pandemic preparedness? Oseltamivir phosphate is a cornerstone of pandemic influenza preparedness strategies for many countries. Governments maintain strategic national stockpiles of the drug to ensure a readily available supply in the event of a novel influenza strain that causes widespread illness and potential mortality.

5. How does insurance coverage affect the out-of-pocket cost for oseltamivir phosphate? Insurance coverage significantly reduces out-of-pocket costs. Patients with comprehensive prescription drug benefits will typically pay a co-payment that aligns with their plan's formulary tier. This co-payment is generally lower for generic oseltamivir phosphate than for brand-name Tamiflu, and can range from $0 to $20 for generics, and potentially higher for the branded product depending on the plan.

Citations

[1] World Health Organization. (n.d.). Influenza (seasonal). Retrieved from https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

[2] U.S. Food and Drug Administration. (2018, April 3). FDA approves new labeling for Tamiflu (oseltamivir phosphate) to include use in infants. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information